Market News
Stay updated with the latest market trends, earnings, and economic indicators.
10 Nifty 500 stocks plunge over 50% from 52-week highs. Do you own any?
Nifty 500 stocks experienced sharp declines, far exceeding index movements. Several companies saw their values drop by over fifty percent from recent highs. Reliance Power and Cohance Lifesciences are among the biggest losers in this market correction.
Volumes spurt at Cohance Lifesciences Ltd counter
Cohance Lifesciences Ltd registered volume of 234.51 lakh shares by 14:14 IST on NSE, a 41.19 fold spurt over two-week average daily volume of 5.69 lakh shares
Cohance Lifesciences Ltd leads gainers in 'A' group
Piramal Pharma Ltd, Jain Irrigation Systems Ltd, Aarti Pharmalabs Ltd and BASF India Ltd are among the other gainers in the BSE's 'A' group today, 23 June 2026.
Volumes soar at Cohance Lifesciences Ltd counter
Cohance Lifesciences Ltd recorded volume of 9.61 lakh shares by 10:46 IST on BSE, a 12.91 times surge over two-week average daily volume of 74436 shares
Cohance Lifesciences CFO Himanshu Agarwal resigns to pursue opportunity outside company
Cohance Lifesciences announced that Himanshu Agarwal, whole-time director (WTD) and chief financial officer (CFO) has tendered his resignation to pursue a professional opportunity outside the organisation.
Cohance Lifesciences Q4 FY26 Results | Kalpataru Q4 FY26 Results | Top Buzzing Stocks Today - Equitymaster
Cohance Lifesciences Q4 FY26 Results | Kalpataru Q4 FY26 Results | Top Buzzing Stocks TodayEquitymaster
Cohance Lifesciences Q4 FY26 Results | Kalpataru Q4 FY26 Results | Top Buzzing Stocks Today - Equitymaster
Cohance Lifesciences Q4 FY26 Results | Kalpataru Q4 FY26 Results | Top Buzzing Stocks TodayEquitymaster
NIIT Learning Systems Ltd leads losers in 'A' group
Sky Gold & Diamonds Ltd, Torrent Power Ltd, Cohance Lifesciences Ltd and Kirloskar Brothers Ltd are among the other losers in the BSE's 'A' group today, 13 May 2026.
Cohance Q4 Profit Slumps 72%, ICICI Securities Downgrades to Reduce'
While Cohance continues to have a strong near-term pipeline of four late-stage phase3 projects, commercialisation timelines for these remain uncertain.
Cohance Lifesciences expects revenue, EBITDA bottom in Q1 FY27; Stock recovers from lows
Cohance Lifesciences has guided for growth to return from the second half of FY27. It said the first quarter is likely to be the low point for both revenues and EBITDA.
Cohance Lifesciences shares slip 7% after Jefferies cuts target price, downgrades on weak Q4
Cohance Lifesciences shares dropped significantly after reporting an 84% year-on-year decline in March-quarter net profit. Jefferies downgraded the stock to "Underperform" citing management instability and weak visibility, while Goldman Sachs maintained its "Buy" rating, seeing long-term opportunities despite a challenging near-term outlook.
Jefferies Downgrades A Stock That Has Gained 33% In Three Weeks
The brokerage cuts Cohance Life to Underperform, citing weak fundamentals that it says the recent rally hasn't priced in.